Research Article

Meta-Analysis of Dyslipidemia and Blood Lipid Parameters on the Risk of Primary Open-Angle Glaucoma

Guimei Huang,1 Jiayi Wang,2 Lei Li,3 Yuan Gao,3 and Yijie Yan3

1Ophthalmology Department, Qionghai People's Hospital, Qionghai, 571400 Hainan, China
2Ophthalmology Department, Qionghai Jianping Hospital, Qionghai, 571400 Hainan, China
3Ophthalmology Department, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Haikou, 570311 Hainan, China

Correspondence should be addressed to Yijie Yan; yanyijie11@163.com

Received 20 June 2022; Revised 7 September 2022; Accepted 9 September 2022; Published 21 September 2022

Objective. We aimed to explore the effect of blood lipid parameters on the risk of primary open-angle glaucoma (POAG) by meta-analysis.

Methods. The databases of PubMed, Scopus, CNKI, and Wanfang were systematically searched from inception to April 2022, and the relevant research literature was obtained, screened, and analyzed.

Results. A total of 15 studies were included in this meta-analysis, including 11 reporting dyslipidemia and risk of POAG and 5 reporting specific lipid level and risk of POAG. Dyslipidemia increased the risk of POAG with an odd ratio (OR) of 1.25 (95% CI: 1.23, 1.26). Total triglyceride and total cholesterol were not related to the prevalence of POAG, but high-density lipoprotein cholesterol was significantly negatively correlated with the risk of POAG with an OR of 0.96 (95% CI: 0.94, 0.99).

Conclusion. Dyslipidemia is a risk factor for POAG. Given the small sample size and significant interstudy heterogeneity, additional studies are needed to establish this conclusion.

1. Introduction

Glaucoma is a group of ocular conditions characterized by progressive optic nerve damage with corresponding visual field defect. Pathologically, glaucoma is characterized by the loss of retinal ganglion cells, the thinning of the retinal nerve fiber layer and the morphological change of the optic disc. Primary open-angle glaucoma (POAG) is a type of glaucoma with an open, normal-appearing anterior chamber angle and raised intraocular pressure, in the absence of other underlying diseases [1]. According to prior reports, the number of patients with glaucoma worldwide is 76 million with an incidence of 3.54% in people aged 40-80, which is expected to be increased to 112 million by 2040. The exact pathogenesis of POAG remains unclear. The risk factors identified include elevated intraocular pressure [2], advanced age [3], race [4], and a family history of glaucoma [5]. The study by Jonas et al. that first evaluated the relationship between blood lipid levels and POAG found no significant correlations [6]. A recent metasudy showed that the total triglyceride level in POAG was significantly higher than that of the control group [7]. This finding is echoed by a recent meta-analysis [8]. Nonetheless, the associations between specific blood lipid parameters and the risk of POAG remain scarcely investigated. The purpose of this study is to explore the relationship between dyslipidemia, specific blood lipid parameters, and the prevalence or risk of POAG through a meta-analysis.

2. Materials and Methods

2.1. Literature Search. The databases PubMed, Scopus, CNKI, and Wanfang were searched from inception to May 6, 2022. The search language was limited to Chinese and English. The search terms were as follows: “glaucoma, open angle” or “open angle glaucomas” and “cholesterol,” “glyceride,” “high-density cholesterol lipoprotein,” “low-density cholesterol lipoprotein,” and “blood lipid,” “lipid metabolism,” or “hypercholesterolemia, dyslipidemia,” and “odds ratio”.
2.2. Inclusion and Exclusion Criteria. Inclusion criteria: (i) The study purpose was to explore the effect of blood lipid level (or abnormal lipid metabolism) on the risk of POAG; (ii) Study design was cross-sectional, case-control, or cohort study; (iii) Publication language limited to Chinese or English; (iv) Study population is not limited by age, race, and gender.

Literature exclusion criteria: (i) The literature content is inconsistent or weakly relevant; (ii) Animal experiments, in vitro tests, letters, reviews, case reports, abstracts, or incomplete reports; (iii) No data available in terms of study exposure (no blood lipid level) or relevant outcomes; (iv) No original text.

2.3. Data Sorting. Yan completed the content extraction from eligible publications, while Huang and Wang checked independently. The contents extracted included study author name, year of publication, study type, inclusion criteria of patients, number of patients, main observation indicators, and other information.

2.4. Literature Quality Evaluation. The quality of the included publications was evaluated by the scale reported by Viswanathan et al. [9, 10]. The quality assessment method included 15 items involving the design, criteria for observational studies, and data analysis evaluation. It evaluated the methods of research objects selection, results and exposure measurement, and the methods of controlling confounders, potential conflicts of interest and the risk of deviation related to different designs. A score of 0 or 1 would be assigned to each item assessed, and the total score would be 15 points.

2.5. Statistical Analysis. All data in this study were analyzed by Stata v16.0 software. Two-sided $P < 0.05$ denoted statistically significance. The binary enumeration data was expressed as odds ratio (OR) with 95% confidence interval (95% CI). If the OR was not provided, it was calculated according to the number of events in the diseased and non-diseased population. The specific calculation equation is $\text{OR} = (\text{number of exposed persons in the diseased group} / \text{number of nonexposed persons in the diseased group}) / (\text{number of exposed persons in the nondiseased group} / \text{number of nonexposed persons in the nondiseased group})$. The heterogeneity test between different studies was described by the $I^2$ statistic with the following equation $I^2 = (Q - df)/Q$, in which $Q$ represents the $\chi^2$ statistic and $df$ denotes its degrees of freedom. $I^2$ corrected by degrees of freedom $\geq 50\%$ or $< 50\%$ was deemed to indicate high or low inter-study heterogeneity, respectively. All studies were pooled using the fixed-effect models. The association between hyperlipidemia and glaucoma was evaluated according to the study design, and subgroup analysis was performed. Publication bias was assessed using Begg’s funnel plot, along with Begg’s test. The Begg’s test is a rank correlation funnel plot asymmetry test method, and when $P > 0.05$, it can be considered that the funnel plot has no obvious asymmetry. When the data is less than 10 points, the funnel plot and asymmetric test methods cannot judge whether there is publication bias due to the low-test power. In this study, we do not report funnel plots with fewer than 10 points, but still report the results of Begg’s test.

3. Results

3.1. Literature Search. The screening process of this study is shown in Figure 1. A total of 591 articles were retrieved, including 585 relevant Chinese and English documents and 6 ambiguous documents. After removing 406 duplicate documents, 158 documents were screened and excluded by reading the title and abstract. The full-texts of the remaining 27 documents were read, and 11 publications were excluded for absence of original text ($n = 1$) and data unavailability ($n = 10$). Of the 15 included literature, 11 reported abnormal lipid metabolism and risk of POAG, and 5 reported the relationship between blood lipid level and POAG.

3.2. Basic Information Included in the Study. The 11 literature that reported the prevalence or risk of dyslipidemia in POAG are shown in Table 1. A total of 2879714 patients, including 155928 POAG, were involved in 4 cross-sectional studies, 4 case-control studies, and 3 cohort studies. Eight studies were conducted in Asian populations (3 in Taiwan and 5 in South Korea), and 3 in European and American populations (all conducted in the United States). The five literature that reported the risk of blood lipid level are shown in Table 2. A total of 23296 patients, including 1315 POAG, were studied in 2 cross-sectional studies and 3 case-control studies in Asian populations (3 in China and 2 in South Korea). The quality of the literature was evaluated, and the results are shown in Table 3.
### 3.3. Abnormal Lipid Metabolism and Risk of POAG

Meta-analysis of 11 literature indicated that the OR for POAG with abnormal lipid metabolism was 1.25 (95% CI: 1.23, 1.26). Significant interstudy heterogeneity ($I^2 = 99.8\%$, $P < 0.001$) was noted and presented in Figure 2. Subgroup analysis found that both cross-sectional and case-control studies

| Author         | Year | Research type | Data sources                          | OAG diagnostic criteria                                                                 | Diagnostic criteria of dyslipidemia                                                                 | Inclusion period | Age                  |
|----------------|------|---------------|---------------------------------------|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|------------------|----------------------|
| Jung et al. [11] | 2020 | Cohort        | KNHIS-NSC 2002-2013                   | Complied with ICD-10 H40.1 and received the prescription of antiglaucoma drugs during the study period | Hypercholesterolemia: Conformed to ICD-10 E78; received cholesterol drug prescription or TC $\geq$ 240 mg/dL | 2002-2008      | $\geq$65 years old, accounting for 16.2% |
| Rim et al. [12] | 2018 | Case-control  | KNHIS-NSC 2002-2013                   | Complied with KCD H401 and received the prescription of antiglaucoma drugs during the study period | Hyperlipidemia: accorded to KCD classification                                                | 2004-2007      | Middle aged and elderly people     |
| Lee et al. [13]  | 2017 | Cross-sectional | KNHANES 2008-2012                      | Complied with MISGEO-K                                                                  | Hyperlipidemia: received cholesterol drug prescription or TC $\geq$ 240 mg/dL               | 2008-2012      | $>$40 years old                  |
| Chen et al. [14] | 2016 | Case-control  | NHI                                   | Complied with ICD-9-CM 365.11                                                          | Hyperlipidemia: ICD-9-CM 272                                                               | 2001-2011      | $>$40 years old, with an average of 57 years old |
| Kim et al. [15]  | 2016 | Cross-sectional | KNHANES 2010-2012                      | Complied with ISGEO                                                                    | Hyperlipidemia: TG $\geq$ 150 mg/dL or cholesterol drug treatment                          | 2008-2012      | $>$40 years old, with an average of 56 years old |
| Chung et al. [16] | 2014 | Cross-sectional | the Longitudinal Health Insurance Database 2000 (LHID2000) of NHI | Complied with ICD-9-CM 365.1 or 365.11                                                 | Not mentioned                                                                                     | 2002-2012      | $\geq$18 years old                  |
| Newman-Casey et al. [17] | 2011 | Cohort        | US i3 InVision data Mart database     | ICD-9-CM 365.1, 365.10, 365.11, 365.12 and 365.15                                     | Hyperlipidemia: ICD-9-CM                                                                  | 2001-2007      | $>$40 years old                  |
| Lin et al. [18]  | 2010 | Case-control  | NHI                                   | ICD-9-CM 365.1-365.11                                                                | Elixhauser comorbidity index [19]                                                          | 2005           | $>$40 years old                  |
| Motsko and Jones [20] | 2008 | Case-control  | US Ingenix LabRx database             | ICD-9-CM 365.1                                                                     | Lipid metabolism disorder: ICD-9-CM 272                                                     | 2001-2004      | With an average of 73.6 years old |
| Girkin et al. [21] | 2004 | Cohort        | The Birmingham (Alabama) Department of Veterans Affairs Medical Center (BVAMC)     | ICD-9-CM 365.1                                                                     | Lipid metabolism disorder: ICD-9-CM 272                                                     | 1997-2002      | $>$50 years old                  |
| Kim et al. [5]   | 2016 | Cross-sectional | KNHANES 2008-2011                      | MISGEOCK I or II standard                                                                | Disorder of lipid metabolism: TC $> 200$ mg/dL or LDLC $> 130$ mg/dL or HDLC $< 60$ mg/dL or TG $> 150$ mg/dL | 2008-2011      | $>$40 years old, with an average age of 59.7 years old |

Note: The Korean National Health Insurance System-National Sample Cohort (KNHIS-NSC), Korean National Health and Nutrition Examination Survey (KNHANES), the International Classification of Diseases, 10th Revision (ICD-10), Korean Classification of Diseases (KCD), the Modified International Society of Geographical and Epidemiological Ophthalmology Criteria for the Korean Population (MISGEO-K), the Modified International Society of Geographical and Epidemiological Ophthalmology Criteria (MISGEO), the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM), Taiwan National Health Insurance plan (NHI), and the International Society of Geographical and Epidemiological Ophthalmology Criteria (ISGEOC).
Table 2: The basic situation of reported studies on blood lipid level and disease risk.

| Authors          | Year | Research type | Data sources                                                                 | OAG diagnostic criteria | Report blood lipid parameters | Blood lipid unit | Inclusion period | Age              |
|------------------|------|---------------|-------------------------------------------------------------------------------|-------------------------|------------------------------|------------------|-----------------|------------------|
| Lei et al. [22]  | 2020 | Case-control  | Collected by Department of Ophthalmology and Visual Sciences; eye, ear, nose, and throat, Hospital of Fudan University | Complied with ISGEOC standards | TG, TC                       | Per mmol/L       | 2017            | Average age of 60 years old |
| Shon and Sung [23]| 2019 | Cross-sectional | KNHANES 2018-2020                                                              | Complied with ISGEOC standards | TG, TC, HDLC                 | Per SD           | 2008-2012       | Average age of 63 years old |
| Wu [24]          | 2019 | Case-control  | Shantou University -Chinese University of Hong Kong joint Shantou international eye center | POAG includes HTG and NTG, which need to meet the inclusion criteria, respectively | TG, TC, HDLC, LDL-C | Per mmol/L       | ——             | >40 years old     |
| Tang et al. [25] | 2017 | Case-control  | Eye, ear, nose, and throat, Hospital of Fudan University                       | Not mentioned            | TC, HDLC                     | Per mmol/L       | 2015-2016       | Average age of 40 years old     |
| Kim et al. [26]  | 2014 | Cross-sectional | KNHANES 2009–2010                                                              | Complied with ISGEOC standards | TG, TC, HDLC, LDL-C | Per mg/dL        | 2009–2010       | 19–39 years old   |

Note: Korean National Health and Nutrition Examination Survey (KNHANES), the Modified International Society of Geographical and Epidemiological Ophthalmology Criteria (ISGEO), the Modified International Society of Geographical and Epidemiological Ophthalmology Criteria for the Korean Population (MISGEO-K), total cholesterol (TC), total triglyceride (TG), high density lipoprotein cholesterol (HDL-C), and low density lipoprotein cholesterol (LDL-C).

Table 3: Evaluation scores of included studies using the Viswanathan M design scale.

| Jung et al. [11] | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 10 |
| Rim et al. [12]  | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 10 |
| Lee et al. [13]  | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 10 |
| Chen et al. [14] | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 11 |
| Kim et al. [15]  | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 10 |
| Chung et al. [16] | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6  |
| Newman-Casey et al. [17] | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 10 |
| Lin et al. [18]  | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 6  |
| Motsko and Jones. [20] | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 7  |
| Girkin et al. [21] | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 9  |
| Kim et al. [5]   | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 10 |
| Lei et al. [22]  | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 10 |
| Shon and Sung [23]| 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 10 |
| Wu et al. [24]   | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 9  |
| Tang et al. [25] | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 9  |

Note: Quality criteria and evaluation of design and data analysis for observational studies criteria (1) Was the research question or objective in this paper clearly stated? (2) Was the study population clearly specified and defined? (3) Was the study population representative of the general population? (4) Was the participation rate of eligible persons at least 50%? (5) Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? (6) Were sample size justification, power description, or variance and effect estimates provided? (7) For the analyses in this paper, were the exposures of interest measured prior to the outcomes being measured? (8) Was the time frame sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? (9) Were the exposure measures (independent variables) clearly defined, objective, valid, reliable, and implemented consistently across all study participants? (10) Were the exposures assessed more than once over time? (11) Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? (12) Were the outcome assessors blinded to the exposure status of participants? (13) Was the statistical analysis appropriate? (14) Was loss to follow-up after baseline 20% or less? (15) Were the key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposures and outcomes? (1: yes; 0: no or not applicable).
Overall, MH ($I^2 = 99.8\%, p = 0.000$)

Heterogeneity between groups: $p = 0.000$

Subgroup, MH ($I^2 = 78.9\%, p = 0.003$)

Kim, M. J., et al. (2016)
Chung, S. D., et al. (2014)
Kim, H. A., et al. (2016)
Lee, S. H., et al. (2017)

Cross-sectional

Subgroup, MH ($I^2 = 99.4\%, p = 0.000$)

Motsko, S. P. and J. K. Jones. (2008)
Lin, H. C., et al. (2010)
Chen, Y. Y., et al. (2016)
Rim, T. H., et al. (2018)

Case-control

Subgroup, MH ($I^2 = 99.1\%, p = 0.000$)

Girkin, C. A., et al. (2004)
Newman-Casey, P. A., et al. (2011)
Jung, Y., et al. (2020)

Type and study (year) | Odds Ratio (95% CI) | Weight |
--- | --- | --- |
Cohort
Jung, Y., et al. (2020) | 1.02 (0.97, 1.08) | 5.94 |
Newman-Casey, P. A., et al. (2011) | 0.69 (0.67, 0.71) | 41.25 |
Girkin, C. A., et al. (2004) | 1.89 (1.48, 2.42) | 0.19 |
Subgroup, MH ($I^2 = 99.1\%, p = 0.000$) | 0.74 (0.72, 0.75) | 47.38 |

Case-control
Rim, T. H., et al. (2018) | 0.57 (0.51, 0.64) | 2.01 |
Chen, Y. Y., et al. (2016) | 1.84 (1.70, 1.99) | 2.22 |
Lin, H. C., et al. (2010) | 1.83 (1.80, 1.87) | 38.86 |
Motsko, S. P. and J. K. Jones. (2008) | 1.27 (1.19, 1.36) | 3.83 |
Subgroup, MH ($I^2 = 99.4\%, p = 0.000$) | 1.73 (1.70, 1.76) | 46.92 |

Cross-sectional
Lee, S. H., et al. (2017) | 1.63 (1.36, 1.95) | 0.41 |
Kim, H. A., et al. (2016) | 1.56 (1.26, 1.94) | 0.32 |
Chung, S. D., et al. (2014) | 1.51 (1.43, 1.61) | 4.19 |
Kim, M. J., et al. (2016) | 1.13 (0.97, 1.31) | 0.78 |
Subgroup, MH ($I^2 = 78.9\%, p = 0.003$) | 1.47 (1.40, 1.55) | 5.70 |

Heterogeneity between groups: $p = 0.000$

Overall, MH ($I^2 = 99.8\%, p = 0.000$) | 1.25 (1.23, 1.26) | 100.00 |

**Figure 2:** Forest chart reporting the study on the relationship between dyslipidemia and the risk of POAG.

NOTE: Weights and between-subgroup heterogeneity test are from Mantel-Haenszel model.

Overall, IV ($I^2 = 82.6\%, p = 0.000$)

Heterogeneity between groups: $p = 0.012$

Overall, IV ($I^2 = 82.6\%, p = 0.000$) | 1.00 (1.00, 1.00) | 100.00 |

**Figure 3:** Forest map reporting the odds ratio for POAG risk by TG level.
showed a positive correlation between dyslipidemia and risk of POAG with an OR of 1.47 (95% CI: 1.40, 1.55) for cross-sectional studies and 1.73 (95% CI: 1.70, 1.76) for case-control studies. Nonetheless, cohort studies showed a negative correlation between dyslipidemia and the risk of POAG with an OR of 0.74 (95% CI: 0.72, 0.75). The funnel plot (Figure S1, supplementary data) showed that the points were distributed on both sides, showing an inverted funnel shape, and P = 0.755 by Begg’s test. Still, some studies were not within the confidence interval due to significant heterogeneity.

3.4. Blood Lipid Level and Risk of POAG. Meta-analysis conducted on the 5 literature reporting associations between blood lipid levels and risk of POAG showed the OR for POAG by triglyceride (TG) was 1.00 (95% CI: 1.00, 1.00). There was great heterogeneity among the studies (I² = 82.6%, P < 0.001), as shown in Figure 3. Subgroup analysis showed significant positive correlation between TG and risk of POAG (OR = 1.73, 95% CI: 1.70, 1.76) in case-control studies but not in cross-sectional studies. No publication bias was found by Begg’s test (P = 0.086).
For specific lipid levels, the meta-analysis showed that the OR for POAG risk by total cholesterol (TC) or high-density lipoprotein cholesterol (HDLc) were 1.00 (95% CI: 0.99, 1.01) and 0.96 (95% CI: 0.94, 0.99), respectively. Figure 4 ($I^2 = 74.9\%$, $P = 0.001$) and Figure 5 ($I^2 = 0\%$, $P = 0.770$) demonstrated significant interstudy heterogeneity for both analyses. Subgroup analysis showed that TC was not associated with POAG risk in case-control studies and cross-sectional studies. In addition, HDLC was negatively correlated with the risk of POAG with an OR of 0.96 (95% CI: 0.94, 0.99), but not in the cross-sectional study ($OR = 0.86$, 95% CI: 0.63, 1.16). No publication bias was found, $P = 0.707$ and $P = 0.221$ by Begg’s test, respectively.

4. Discussion

Abundant prior studies have reported the relationship between abnormal lipid level and risk of POAG with no consistent conclusions. Abnormal lipid metabolism usually refers to the increase of TC or TG, which may be accompanied by the decrease of HDLC [27]. Lipid metabolism is an important risk factor for cardiovascular disease [270]. Previous studies have suggested that abnormal lipid metabolism may increase POAG risk by reducing blood flow velocity and changing lipid components in the aqueous humour [24, 25]. Apolipoprotein B and apolipoprotein E in the aqueous humour of POAG patients were significantly increased, which may then change cholesterol transport. On the other hand, genetic factors may also modulate the association between lipid metabolism and risk of POAG. It has been shown that several genes involved in lipid metabolism were significantly related to POAG risk, such as ATP binding cassette subfamily A member 1 gene and caveolin 1 gene [28, 29].

The aim of this study is to assess the correlation between lipid abnormalities or specific blood lipid levels and the risk of POAG. The results showed that dyslipidemia increased the risk of POAG in cross-sectional and case-control studies, but not in cohort studies. This disparity might be related to the effect of confounding factors. For instance, patients with diagnosed hyperlipidemia were more likely to receive treatment. In a large cohort study by Newman-Casey et al., significant negative correlation between hyperlipidemia and POAG (hazard ratio 0.95, 95% CI 0.91, 0.98) was noted even after correcting for a series of covariates. In previous studies, statins have been shown to reduce the adverse effect of hyperlipidemia on POAG by decreasing intraocular pressure while reducing cholesterol [30]. It is currently unclear whether hyperlipidemia and the use of lipid-lowering medications are independent risk factors for POAG, which should be further clarified in future studies.

For a specific blood lipid parameter, this study did not find that TC and TG were related to an increased risk of POAG. A recent cross-sectional study in Singapore found that high levels of HDLC cholesterol were associated with a reduced risk of POAG (OR, 0.91; 95% CI, 0.84–0.99, $P = 0.021$), but no association was found between conventional lipids (e.g., TC, HDLC, and low-density lipoprotein cholesterol) and POAG [31]. Although we noted a negative correlation between HDLC and POAG, it is limited by small sample size and needs further confirmation.

This study suffers from several limitations. First, significant interstudy heterogeneity was noted, which might be related to the diversity of study designs and subject population. However, further subgroup analysis or meta-regression to clarify the source of heterogeneity was difficult due to quantitative limitations. Second, part of the results of this study included less than 10 studies. The funnel plot and asymmetry test methods cannot judge whether the funnel is symmetrical or not due to the low-test performance. More original research is needed in the future to clarify our preliminary conclusions. Third, most of the studies included were cross-sectional or case-control in design, and the number of cohort studies was small, so the causal relationship between dyslipidemia and POAG risk could not be inferred. Fourth, this study failed to clarify the impact of other identified risk factors for POAG. In addition, the OR values reported in some studies were not corrected by covariates, especially intraocular pressure. Finally, this study analyzed the correlations between specific lipid and risk of POAG, providing evidence to clarify the impact of individual lipid on the risk of POAG. However, given the small number of studies included, additional studies are needed in the future to firmly establish this conclusion.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors have no conflicts of interest to declare.

Authors’ Contributions

Guimei Huang and Jiayi Wang contributed equally to this work.

Acknowledgments

The study was supported by Qionghai People’s Hospital.

Supplementary Materials

This section provides additional information about the funnel chart for reporting the relationship between dyslipidemia and the risk of POAG (Supplementary Figure S1). (Supplementary Materials)

References

[1] J. D. Stein, A. P. Khawaja, and J. S. Weizer, “Glaucoma in adults-screening, diagnosis, and management: a review,” JAMA, vol. 325, no. 2, pp. 164–174, 2021.

[2] Y. C. Tham, X. Li, T. Y. Wong, H. A. Quigley, T. Aung, and C. Y. Cheng, “Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and
meta-analysis,” *Ophthalmology*, vol. 121, no. 11, pp. 2081–2090, 2014.

[3] R. N. Weinreb and P. T. Khaw, "Primary open-angle glaucoma," *Lancet*, vol. 363, no. 9422, pp. 1711–1720, 2004.

[4] M. Baskaran, R. C. Foo, C. Y. Cheng et al., “The prevalence and types of glaucoma in an urban Chinese population,” *JAMA ophthalmology*, vol. 133, no. 8, pp. 874–880, 2015.

[5] K. E. Kim, M. J. Kim, K. H. Park et al., “Prevalence, awareness, and risk factors of primary open-angle glaucoma: Korea national health and nutrition examination survey 2008-2011,” *Ophthalmology*, vol. 123, no. 3, pp. 532–541, 2016.

[6] J. B. Jonas, T. Aung, R. R. Bourne, A. M. Bron, R. Ritch, and S. Panda-Jonas, “Glaucoma–authors’ reply,” *Lancet*, vol. 390, no. 10108, pp. 2183–2193, 2018.

[7] W. C. Stewart, C. Sine, S. Sutherland, and J. A. Stewart, “Total cholesterol and high-density lipoprotein levels as risk factors for increased intraocular pressure,” *American Journal of Ophthalmology*, vol. 122, no. 4, pp. 575–577, 1996.

[8] L. Pertl, G. Mossböck, A. Wedrich et al., “Triglycerides and open angle glaucoma - a meta-analysis with meta-regression,” *Scientific Reports*, vol. 7, no. 1, p. 7829, 2017.

[9] S. Sanderson, I. D. Tatt, and J. Higgins, “Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography,” *International Journal of Epidemiology*, vol. 36, no. 3, pp. 666–676, 2007.

[10] M. Viswanathan, M. T. Ansari, N. D. Berkman et al., “AHRQ methods for effective health care assessing the risk of bias of individual studies in systematic reviews of health care interventions,” in *Methods Guide for Effectiveness and Comparative Effectiveness Reviews*. Rockville (MD), Agency for Healthcare Research and Quality (US), 2008.

[11] Y. Jung, K. Han, H. Y. Park, S. H. Lee, and C. K. Park, “Metabolic health, obesity, and the risk of developing open-angle glaucoma: metabolically healthy obese patients versus metabolically unhealthy but Normal weight patients,” *Diabetes and Metabolism Journal*, vol. 44, no. 3, pp. 414–425, 2020.

[12] T. H. Rim, S. Y. Lee, H. W. Bae, S. S. Kim, and C. Y. Kim, “Increased stroke risk among patients with open-angle glaucoma: a 10-year follow-up cohort study,” *The British Journal of Ophthalmology*, vol. 102, no. 3, pp. 338–343, 2018.

[13] S. H. Lee, G. A. Kim, W. Lee, H. W. Bae, G. J. Seong, and C. Y. Kim, “Vascular and metabolic comorbidities in open-angle glaucoma with low- and high-teen intraocular pressure: a cross-sectional study from South Korea,” *Acta Ophthalmologica*, vol. 95, no. 7, pp. e564–e574, 2017.

[14] Y. Y. Chen, H. Y. Hu, D. Chu, H. H. Chen, C. K. Chang, and P. Chou, "Patients with primary open-angle glaucoma may develop ischemic heart disease more often than those without glaucoma: an 11-year population-based cohort study," *PLoS One*, vol. 11, no. 9, article e0163210, 2016.

[15] H. A. Kim, K. Han, Y. A. Lee, J. A. Choi, and Y. M. Park, “Differential association of metabolic risk factors with open angle glaucoma according to obesity in a Korean population,” *Scientific Reports*, vol. 6, 2016.

[16] S. D. Chung, H. C. Lin, and S. H. Hung, "Allergic rhinitis is associated with open-angle glaucoma: a population-based case-control study," *American Journal of Rhinology & Allergy*, vol. 28, no. 4, pp. e148–e151, 2014.

[17] P. A. Newman-Casey, N. Talwar, B. Nan, D. C. Musch, and J. D. Stein, “The relationship between components of metabolic syndrome and open-angle glaucoma,” *Ophthalmology*, vol. 118, no. 7, pp. 1318–1326, 2011.

[18] H. C. Lin, C. W. Chien, C. C. Hu, and J. D. Ho, "Comparison of comorbid conditions between open-angle glaucoma patients and a control cohort: a case-control study," *Ophthalmology*, vol. 117, no. 11, pp. 2088–2095, 2010.

[19] A. Elithuauser, C. Steiner, D. R. Harris, and R. M. Coffey, "Comorbidity measures for use with administrative data," *Medical Care*, vol. 36, no. 1, pp. 8–27, 1998.

[20] S. P. Motsko and J. K. Jones, “Is there an association between hypothyroidism and open-angle glaucoma in an elderly population?: an epidemiologic study,” *Ophthalmology*, vol. 115, no. 9, pp. 1581–1584, 2008.

[21] C. A. Girkin, G. McGwin Jr., S. F. McNeal, P. L. Lee, and C. Owseley, “Hypothyroidism and the development of open-angle glaucoma in a male population,” *Ophthalmology*, vol. 111, no. 9, pp. 1649–1652, 2004.

[22] Y. Lei, Y. Gao, M. Song, W. Cao, and X. Sun, “Retrospective case-control data of serum nitrotyrosine level and clinical biochemical indices in primary glaucoma patients,” *Data in Brief*, vol. 31, article 105706, 2020.

[23] K. Shon and K. R. Sung, “Dyslipidemia, dyslipidemia treatment, and open-angle glaucoma in the Korean national health and nutrition examination survey,” *Journal of Glaucoma*, vol. 28, no. 6, pp. 550–556, 2019.

[24] Z. Wu, *The Role of CAV1 Gene in the Pathogenesis of Primary Open-Angle Glaucoma*, Shantou University, 2019.

[25] B. Tang, M. Shao, S. Li, L. Tang, W. Cao, and X. Sun, “Association study between peripheral blood lipid levels and primary open-angle glaucoma,” *Chinese Journal of Laboratory Medicine*, vol. 40, no. 3, pp. 211–216, 2017.

[26] M. J. Kim, M. J. Kim, H. S. Kim, J. W. Jeoung, and K. H. Park, “Risk factors for open-angle glaucoma with normal baseline intraocular pressure in a young population: the Korea national health and nutrition examination survey,” *Clinical & Experimental Ophthalmology*, vol. 42, no. 9, pp. 825–832, 2014.

[27] K. L. C. Lowenstein, “Dyslipidemia,” *Annals of Internal Medicine*, vol. 167, no. 11, pp. Itc81–itc96, 2017.

[28] Y. Shiga, M. Akiyama, K. M. Nishiguchi et al., “Genome-wide association study identifies seven novel susceptibility loci for primary open-angle glaucoma,” *Human Molecular Genetics*, vol. 27, no. 8, pp. 1486–1496, 2018.

[29] S. S. Rong, L. J. Chen, C. K. Leung et al., “Ethnic specific association of the CAV1/CAV2 locus with primary open-angle glaucoma,” *Scientific Reports*, vol. 6, no. 1, 2016.

[30] N. Yilmaz, D. T. Coban, A. Bayindir et al., “Higher serum lipids and oxidative stress in patients with normal tension glaucoma, but not pseudoxfoliative glaucoma,” *Bosnian Journal of Basic Medical Sciences*, vol. 16, no. 1, pp. 21–27, 2016.

[31] S. Nusinovici, H. Li, S. Thakur et al., “High-density lipoprotein 3 cholesterol and primary open-angle glaucoma: metabolomics and Mendelian randomization analyses,” *Ophthalmology*, vol. 129, no. 3, pp. 285–294, 2022.